Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases

Donald E. Mager, William J. Jusko, General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 28, pp. 507- 532 ,(2001) , 10.1023/A:1014414520282

Subrata Ghosh, Remo Panaccione, Anti-adhesion molecule therapy for inflammatory bowel disease. Therapeutic Advances in Gastroenterology. ,vol. 3, pp. 239- 258 ,(2010) , 10.1177/1756283X10373176

Sonia M. Aguero, Sigrid K. Mcallister, Martin S. Favero, Lee A. Bland, Carl W. Oettinger, Jamie C. Oliver, Matthew J. Arduino, Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine and cytokine research. ,vol. 12, pp. 115- 120 ,(1993)

T. Ochsenk�hn, M. Sackmann, B. G�ke, Chronisch entzündliche Darmerkrankungen – Kritische Diskussion von Ätiologie, Pathogenese, Diagnostik und Therapie Radiologe. ,vol. 43, pp. 1- 8 ,(2003) , 10.1007/S00117-002-0844-9

Ofer Ben-Bassat, Anna Iacono, Sue P Irwin, Mark S Silverberg, Gordon R Greenberg, None, Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience Gastroenterology. ,vol. 142, ,(2012) , 10.1016/S0016-5085(12)63121-7

Cantoresi F, Cassano N, Dattola S, Loconsole F, Vena Ga, Congedo M, Galluccio A, Fenizi G, Donato L, Massimino Sd, De Simone C, Plumari A, Puglisi Guerra A, Altamura, De Pita O, Pellicano R, Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. Journal of Biological Regulators and Homeostatic Agents. ,vol. 22, pp. 233- 237 ,(2008)

Bruce E. Sands, Biomarkers of Inflammation in Inflammatory Bowel Disease Gastroenterology. ,vol. 149, pp. 1275- 1285 ,(2015) , 10.1053/J.GASTRO.2015.07.003

M. Rosario, N. L. Dirks, M. R. Gastonguay, A. A. Fasanmade, T. Wyant, A. Parikh, W. J. Sandborn, B. G. Feagan, W. Reinisch, I. Fox, Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease Alimentary Pharmacology & Therapeutics. ,vol. 42, pp. 188- 202 ,(2015) , 10.1111/APT.13243

Carlos Taxonera, Jesús Estelles, Ignacio Fernández‐Blanco, Olga Merino, Ignacio Marín‐Jiménez, Manuel Barreiro‐de Acosta, Cristina Saro, Valle García‐Sánchez, Elena Gento, Guillermo Bastida, JP Gisbert, Isabel Vera, Pilar Martinez‐Montiel, Sara Garcia‐Morán, MC Sánchez, Juan Luis Mendoza, None, Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 340- 348 ,(2011) , 10.1111/J.1365-2036.2010.04531.X

Gabor Hutas, Golimumab, a fully human monoclonal antibody against TNFalpha. Current Opinion in Molecular Therapeutics. ,vol. 10, pp. 393- 406 ,(2008)